BA
NTLA icon

Bridgewater Associates’s Intellia Therapeutics NTLA Stock Holding History

Bridgewater Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-223,166
Closed -$2.01M – 1159
2025
Q4 		$2.01M Buy
+223,166
New +$3.07M 0.01% 767
2023
Q1 		– Sell
-9,387
Closed -$328K – 841
2022
Q4 		$328K Buy
+9,387
New +$446K ﹤0.01% 763
2022
Q2 		– Sell
-4,907
Closed -$357K – 1045
2022
Q1 		$357K Buy
+4,907
New +$416K ﹤0.01% 923

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bridgewater Associates's NTLA Position: Q1 2026 in Review

Bridgewater Associates sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 223,166 shares — an estimated $2.01M sold.

Bridgewater Associates first reported a position in NTLA in Q1 2022 and held it in 3 quarters. The position peaked at $2.01M in Q4 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Bridgewater Associates reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgewater Associates sold 223,166 Intellia Therapeutics shares in Q1 2026, an estimated $2.01M.
  • Bridgewater Associates first reported a position in Intellia Therapeutics in Q1 2022 and held it in 3 quarters.
  • Bridgewater Associates's Intellia Therapeutics position peaked at $2.01M in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.